Activiomics Extends Agreement with Kyowa Hakko Kirin
News Sep 19, 2013
Activiomics will apply its novel TIQUAS (Targeted In-depth QUAntification of cell Signalling) phosphoproteomics platform to elucidate signalling mechanisms generated by lead compounds supplied by KHK in relevant cell-based systems. This collaboration falls within Activiomics’ strategic partnership with BioFocus.
Activiomics applies innovative mass spectrometry based methods to analyse and interpret cell signalling pathway activity resulting from drug administration and/or disease progression. The company is utilising its technology for the discovery and clinical validation of novel prognostic and predictive biomarkers as well as to provide high-value drug mode of action information for the pharmaceutical and biotechnology industry.
“We have been impressed with the results from the initial stages of our partnership with Activiomics and look forward to working with them on this new programme,” said Hiroshi Okazaki, Ph.D., Managing Officer and Vice President, Head, Research Division, Head, Fuji Research Park at Kyowa Hakko Kirin.
Dr Kevin FitzGerald, CEO of Activiomics, said: “We are delighted to have signed a new contract with Kyowa Hakko Kirin which follows on from a previous successful study. The extension of the partnership is a strong endorsement of the quality and quantity of information that can be generated using our technology platform. We are also grateful to the invaluable support from BioFocus in establishing this collaboration.”
Dr Chris Newton, Managing Director of BioFocus, commented: “We are delighted that the capabilities of our strategic partner, Activiomics, has captured the interest of our client Kyowa Hakko Kirin, and look forward to further synergies from our alliance with Activiomics.”
‘Good Cholesterol’ May Not Always be Good for Postmenopausal WomenNews
Postmenopausal factors may have an impact on the heart-protective qualities of high-density lipoproteins (HDL) – also known as ‘good cholesterol’ – according to a study led by researchers in the University of Pittsburgh Graduate School of Public Health.READ MORE
What Makes Good Brain Proteins Turn Bad?News
The protein FUS is implicated in two neurodegenerative diseases: amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). Using a newly developed fruit fly model, researchers have zoomed in on the protein structure of FUS to gain more insight into how it causes neuronal toxicity and disease.